Filing Analysis
Minerva Neurosciences, Inc. reported its financial results for the first fiscal quarter ended March 31, 2026. The filing is a routine quarterly update furnished to the SEC under Item 2.02.
Key Facts
- The report was filed on May 5, 2026, covering the fiscal quarter ended March 31, 2026.
- The company furnished a press release as Exhibit 99.1 regarding its financial results.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- Minerva Neurosciences is listed on The Nasdaq Capital Market under the ticker NERV.
Minerva Neurosciences announced its 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026. Due to the timing shifting more than 30 days from the prior year's anniversary, the company established new deadlines for stockholder proposals and director nominations.
Key Facts
- Annual Meeting scheduled for June 3, 2026
- Stockholder proposal deadline under Rule 14a-8 set for April 16, 2026
- Director nomination and other business notice deadline set for April 21, 2026
- The meeting date is more than 30 days from the anniversary of the 2025 annual meeting
Minerva Neurosciences announced the resignation of President Geoffrey Race, effective March 31, 2026, and the appointment of James O’Connor as Chief Business Officer and General Counsel. The company entered into a settlement agreement with Mr. Race involving significant severance benefits and a one-year consultancy agreement.
Red Flags
- Full acceleration of stock option vesting for a departing executive.
- Unusually long extension of the option exercise period until January 1, 2030.
- Immediate transition to a high-rate consultancy role (£333/hour) following resignation.
Key Facts
- Geoffrey Race resigned as President and Director of Mind-NRG SARL effective March 31, 2026.
- Race will receive a one-time payment of his annual salary, 12 months of pension contributions, and a pro-rated 2026 bonus.
- Additional severance includes £30,000, medical/life insurance coverage, and legal fee reimbursement up to £15,000.
- All outstanding stock options for Mr. Race were fully vested as of March 31, 2026, with the exercise period extended to January 1, 2030.
- A consultancy agreement was established with Mr. Race at a rate of £333 per hour for a minimum of 35 hours per month starting April 15, 2026.
- James O’Connor was appointed Chief Business Officer and General Counsel effective April 21, 2026.
Minerva Neurosciences, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to this filing.
Key Facts
- Filing date: March 11, 2026
- Reporting period: Quarter and fiscal year ended December 31, 2025
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- The press release is included as Exhibit 99.1